NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $16.94 -0.13 (-0.76 %) (As of 07/16/2018 12:07 PM ET)Previous Close$17.09Today's Range$16.76 - $17.2252-Week Range$7.15 - $20.21Volume27,545 shsAverage Volume3.15 million shsMarket Capitalization$3.60 billionP/E Ratio-23.71Dividend YieldN/ABeta1.68 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado. Receive ARRY News and Ratings via Email Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:ARRY CUSIP04269X10 Webwww.arraybiopharma.com Phone303-381-6600 Debt Debt-to-Equity Ratio0.36 Current Ratio5.73 Quick Ratio5.73 Price-To-Earnings Trailing P/E Ratio-23.71 Forward P/E Ratio-23.21 P/E GrowthN/A Sales & Book Value Annual Sales$150.85 million Price / Sales23.65 Cash FlowN/A Price / CashN/A Book Value$0.07 per share Price / Book242.00 Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-116,810,000.00 Net Margins-72.33% Return on Equity-96.65% Return on Assets-31.97% Miscellaneous Employees209 Outstanding Shares210,640,000Market Cap$3,595.57 Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions What is Array Biopharma's stock symbol? Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY." How were Array Biopharma's earnings last quarter? Array Biopharma Inc (NASDAQ:ARRY) issued its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.11. The biopharmaceutical company earned $66.37 million during the quarter, compared to analysts' expectations of $28.81 million. Array Biopharma had a negative return on equity of 96.65% and a negative net margin of 72.33%. The company's revenue was up 99.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. View Array Biopharma's Earnings History. When is Array Biopharma's next earnings date? Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Array Biopharma. What price target have analysts set for ARRY? 9 analysts have issued twelve-month price objectives for Array Biopharma's shares. Their predictions range from $13.00 to $33.00. On average, they anticipate Array Biopharma's stock price to reach $21.5556 in the next year. This suggests a possible upside of 27.2% from the stock's current price. View Analyst Ratings for Array Biopharma. What is the consensus analysts' recommendation for Array Biopharma? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Array Biopharma stock? Here are some recent quotes from research analysts about Array Biopharma stock: 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (7/11/2018) 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating with an updated $26 PT on ARRY shares. The company has an upcoming PDUFA of 6/30/18 for the combination of binimetinib/encorafenib (bini/enco), which, based on the results of the COLUMBUS study, has the potential to be best-in-class and take a market-leader position, in our view. In addition, we see further opportunity in BRAF+ CRC based on the safety lead-in portion data presented to date from the BEACON-CRC study." (6/24/2018) Are investors shorting Array Biopharma? Array Biopharma saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 13,980,612 shares, a decline of 13.4% from the June 15th total of 16,138,003 shares. Based on an average daily volume of 4,269,157 shares, the short-interest ratio is presently 3.3 days. Currently, 6.7% of the shares of the stock are short sold. View Array Biopharma's Current Options Chain. Who are some of Array Biopharma's key competitors? Some companies that are related to Array Biopharma include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS) and Dr.Reddy's Laboratories (RDY). Who are Array Biopharma's key executives? Array Biopharma's management team includes the folowing people: Mr. Ron Squarer, Chief Exec. Officer and Director (Age 51)Mr. Jason Haddock, Chief Financial Officer (Age 48)Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)Dr. Victor Sandor M.D., C.M, Chief Medical Officer (Age 52)Dr. Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 59) Has Array Biopharma been receiving favorable news coverage? Media coverage about ARRY stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Array Biopharma earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are Array Biopharma's major shareholders? Array Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.47%), Financial & Investment Management Group Ltd. (0.11%), Fisher Asset Management LLC (0.06%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma. Which institutional investors are selling Array Biopharma stock? ARRY stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and Fisher Asset Management LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma. Which institutional investors are buying Array Biopharma stock? ARRY stock was bought by a variety of institutional investors in the last quarter, including Financial & Investment Management Group Ltd. and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Array Biopharma. How do I buy shares of Array Biopharma? Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Array Biopharma's stock price today? One share of ARRY stock can currently be purchased for approximately $16.94. How big of a company is Array Biopharma? Array Biopharma has a market capitalization of $3.60 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array Biopharma employs 209 workers across the globe. How can I contact Array Biopharma? Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected] MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 368 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 573MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What does EPS mean?